Affiliation:
1. Georgievsky Medical Institute, Vernadsky Crimean Federal University
2. Almazov National Medical Research Center
3. Sevastopol State University; Sechenov Academic Research Institute of Physical Methods of Treatment, Medical Climatology, and Rehabilitation
Abstract
Aim To study the relationship of blood serum concentration of endocan with indexes of apoptosis and clinical and instrumental characteristics of patients with ischemic heart disease (IHD).Material and methods The study included 176 subjects (105 men and 71 women). 150 of them were diagnosed with IHD and 26 were healthy volunteers. Anthropometric measurements, coronary angiography, echocardiography, duplex ultrasound scanning of extracranial parts of the brachiocephalic arteries were performed for all patients. Concentrations of endocan (ng / ml), glucose (mmol / l), and apoptotic markers Bcl-2 (ng / ml), Bax (ng / ml), Bcl-2 / Bax, TRAIL (pg / ml), and p53 (ng / ml) were measured in blood serum. Patients were divided into groups based on their SYNTAX scores: group 1 with moderate atherosclerotic lesions of the coronary arteries (CA) (score < 22, 78 patients); group 2 with severe CA atherosclerosis (score 23-32, 37 patients); and group 3 with extremely severe CA lesions (score >33, 35 patients). The control group consisted of healthy volunteers (26 subjects). All groups were age- and sex-matched. Differences were considered statistically significant at p<0.05.Results A correlation was found between endocan concentration and IHD severity (r=0.32, p<0.001). In group 1, the median endocan concentration was 14.57 ng / ml [8.21; 23.66], in group 2, 19.34 ng / ml [8.425; 26.645], in group 3, 32.13 ng / ml [18.2; 39.12], and in the control group, 6.92 ng / ml [4.62; 9.18]. Correlations of varying strength and significance were observed between the endocan concentration and a number of clinical and instrumental characteristics. Endocan concentrations significantly differed in groups of patients with multifocal atherosclerosis (p<0.01), angina pectoris (p<0.01), a history of myocardial infarction (p<0.001), and obesity (p<0.05) from patients without these signs. Also, a correlation was found between serum endocan concentration and apoptotic markers: TRAIL (r= -0.448, p<0.001); BCL-2 (r= -0.552, p<0.001), Bax (r= -0.519, p<0.001), Bcl-2 / Bax (r= -0.576, p<0.001) and p53 (r= -0.520, p <0.001).Conclusion The study demonstrated a potential role of endocan as a promising biomarker for risk stratification, prognosis and therapeutic monitoring of IHD patients.
Publisher
APO Society of Specialists in Heart Failure
Subject
Cardiology and Cardiovascular Medicine
Reference32 articles.
1. Balta S, Balta I, Mikhailidis DP. Endocan: a new marker of endothelial function. Current Opinion in Cardiology. 2021;36(4):462–8. DOI: 10.1097/HCO.0000000000000867
2. Chen J, Jiang L, Yu X-H, Hu M, Zhang Y-K, Liu X et al. Endocan: A Key Player of Cardiovascular Disease. Frontiers in Cardiovascular Medicine. 2022;8:798699. DOI: 10.3389/fcvm.2021.798699
3. Khalaji A, Behnoush AH, Saeedian B, Khanmohammadi S, Shokri Varniab Z, Peiman S. Endocan in prediabetes, diabetes, and diabetesrelated complications: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. 2023;15(1):102. DOI: 10.1186/s13098-023-01076-z
4. Klisic A, Patoulias D. The Role of Endocan in Cardiometabolic Disorders. Metabolites. 2023;13(5):640. DOI: 10.3390/metabo13050640
5. Klisic A, Kavaric N, Vujcic S, Spasojevic-Kalimanovska V, Ninic A, Kotur-Stevuljevic J. Endocan and advanced oxidation protein products in adult population with hypertension. European Review for Medical and Pharmacological Sciences. 2020;24(12):7131–7. DOI: 10.26355/eurrev_202006_21707